Prenatal parvovirus B19 infection
Archives of Gynecology and Obstetrics · 2024
DOI: 10.1007/s00404-024-07644-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Gynecology and Obstetrics, 2024. Verfasst von Karl Oliver Kagan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany. KOKagan@gmx.de. Hauptthemen laut MEDLINE: Infectious Disease Transmission, Vertical, Parvovirus B19, Human, Pregnancy Complications, Infectious, Erythema Infectiosum. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Tübingen.
Abstract (Originalsprache)
Parvovirus B19 (B19V) causes erythema infectiosum, a.k.a., fifth disease. This disease primarily affects children. It is generally self-limiting and subsides after 1–2 weeks. In pregnancy, the virus can cross the placenta and result in a fetal infection. This may lead to severe fetal anemia, hydrops fetalis, a miscarriage, or intrauterine fetal death. The risk of long-term sequelae also appears to be increased. About one-third of pregnant women are not immune to B19V and, therefore, are at risk to contract a primary infection. The seroconversion rate during pregnancy is generally around 1–2%. During a primary infection, maternal–fetal transplacental transmission of B19V occurs in about 30–50% of the cases and the risk of fetal infection increases with advancing gestational age. The risk of severe fetal anemia or hydrops is around 3–4% overall and is around 6–7% if the primary infection occurs before 20 weeks’ gestation. Fetal monitoring in women with a primary B19V infection includes regular ultrasound examinations looking for evidence of hydrops fetalis and Doppler measurements of the middle cerebral artery peak velocity. Fetal blood sampling is performed if a significant anemia is suspected and, if such is found, an intrauterine blood transfusion is needed. This article provides an overview of the epidemiology, pathogenesis, clinical manifestations, diagnostic methods, and management of B19V infection during pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany. KOKagan@gmx.de.
- Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany.
- Department of Obstetrics and Prenatal Medicine, University Hospital of Bonn, Bonn, Germany.
- Division of Maternal Fetal Medicine, Boonshoft School of Medicine, Wright State University, Dayton, USA.
- Laboratory Prof. Gisela Enders and Colleagues, Stuttgart, Germany, & German Consulting Laboratory for Parvoviruses, Stuttgart, Germany.
ORCID-Profile: Karl Oliver Kagan
Förderung
- Universitätsklinikum Tübingen
Zitieren
APA
Kagan, K. O., Hoopmann, M., Geipel, A., Sonek, J., & Enders, M. (2024). Prenatal parvovirus B19 infection. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-024-07644-6
Vancouver
Kagan KO, Hoopmann M, Geipel A, Sonek J, Enders M. Prenatal parvovirus B19 infection. Archives of Gynecology and Obstetrics. 2024. doi:10.1007/s00404-024-07644-6
BibTeX
@article{Kagan2024,
author = {Kagan, Karl Oliver and Hoopmann, Markus and Geipel, Annegret and Sonek, Jiri and Enders, Martin},
title = {Prenatal parvovirus B19 infection},
journal = {Archives of Gynecology and Obstetrics},
year = {2024},
doi = {10.1007/s00404-024-07644-6}
}
EUVIMED